Technical Analysis for LGVN - Longeveron Inc.

Grade Last Price % Change Price Change
B 21.9144 11.92% 2.33
LGVN closed down 3.31 percent on Tuesday, December 7, 2021, on 14 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Down
Historical LGVN trend table...

Date Alert Name Type % Chg
MACD Bearish Signal Line Cross Bearish 5.46%
Narrow Range Bar Range Contraction 5.46%
NR7 Range Contraction 5.46%
Multiple of Ten Bearish Other 5.46%
Inside Day Range Contraction 5.46%
Wide Bands Range Expansion 5.46%
Multiple of Ten Bullish Other 1.98%
Wide Bands Range Expansion 1.98%
Pocket Pivot Bullish Swing Setup 2.63%
Wide Bands Range Expansion 2.63%
Older End-of-Day Signals for LGVN ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Rose Above Previous Day's High 6 minutes ago
Up 10% 6 minutes ago
Up 5% 30 minutes ago
Up 3% 30 minutes ago
Up 2% 30 minutes ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Longeveron Inc. Description

Longeveron is a clinical stage biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions. The Company’s lead investigational product is the LOMECEL-B™ cell-based therapy product (“Lomecel-B”), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young, healthy adult donors. Longeveron believes that by using the same cells that promote tissue repair, organ maintenance, and immune system function, it can develop safe and effective therapies for some of the most difficult disorders associated with the aging process and other medical disorders. Longeveron is currently sponsoring Phase 1 and 2 clinical trials in the following indications: Aging Frailty, Alzheimer’s disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). The Company’s mission is to advance Lomecel-B and other cell-based product candidates into pivotal Phase 3 trials, with the goal of achieving regulatory approvals, subsequent commercialization and broad use by the healthcare community.


Classification

Sector: Other
Industry: Other
Keywords: Biotechnology Life Sciences Biology Stem Cells Cell Biology Cell Therapy Mesenchymal Stem Cell Acute Respiratory Distress Syndrome

Is LGVN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 45.0
52 Week Low 2.8401
Average Volume 14,240,445
200-Day Moving Average 6.60
50-Day Moving Average 8.37
20-Day Moving Average 15.47
10-Day Moving Average 24.11
Average True Range 6.10
ADX 45.17
+DI 30.93
-DI 13.79
Chandelier Exit (Long, 3 ATRs) 26.69
Chandelier Exit (Short, 3 ATRs) 21.15
Upper Bollinger Bands 38.18
Lower Bollinger Band -7.24
Percent B (%b) 0.59
BandWidth 293.61
MACD Line 4.46
MACD Signal Line 4.75
MACD Histogram -0.2902
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 23.83
Resistance 3 (R3) 23.99 22.73 23.12
Resistance 2 (R2) 22.73 21.64 22.65 22.89
Resistance 1 (R1) 21.15 20.97 20.52 21.00 22.65
Pivot Point 19.89 19.89 19.58 19.81 19.89
Support 1 (S1) 18.32 18.81 17.69 18.16 16.51
Support 2 (S2) 17.06 18.14 16.98 16.27
Support 3 (S3) 15.48 17.06 16.04
Support 4 (S4) 15.33